International Therapeutics, Inc. Announces ProxiQuant License To Rosetta Inpharmatics, Inc. (MRK) To Quantify Gene Expression Interfering Molecules -- RNAi
10/19/2005 5:09:13 PM
International Therapeutics, Inc. announced today that it has agreed to provide Rosetta Inpharmatics LLC (Seattle, WA) a world-wide nonexclusive license to its proprietary ProxiQuant(TM) technology for research and development applications.
comments powered by